Otros idiomas Wave Life Sciences Ltd.

Acciones

WVE

SG9999014716

Tiempo real estimado Cboe BZX Otros sitios de cotización 19:06:28 03/05/2024			Varia. Cinco días.	Varia. 1 de enero.
6,24 ^USD	+6,12 %		+32,83 %	+22,57 %

30/04	Wave Life Sciences anuncia la aprobación de la primera solicitud de ensayo clínico para el ensayo RestorAATion-2 de WVE-006 en individuos con deficiencia de alfa-1 antitripsina	CI
23/04	Wave Life Sciences Ltd. Anuncia el Impulso Continuo en la Colaboración con GSK y los Avances en ARNsi y Edición de ARN	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024	02/05
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)	30/04
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency	30/04
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing	23/04
Wave Life Sciences Ltd. Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing	23/04
Wave Life Sciences to Present at Upcoming Investor Conferences	27/03
Sector Update: Health Care Stocks Higher Late Afternoon	06/03
WAVE Life Sciences Shares Surge After Q4 Beats Estimates	06/03
Wave Life Sciences: Q4 Earnings Snapshot	06/03
Wave Life Sciences Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03
Wave Life Sciences Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	06/03
Earnings Flash (WVE) WAVE LIFE SCIENCES USA Reports Q4 Revenue $29.1M, vs. Street Est of $19.8M	06/03
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	06/03
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024	28/02
Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy	27/02
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones	08/01
Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference	03/01
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy	18/12
Wave Life Sciences Starts Dosing in Neuromuscular Disorder Study	15/12
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy	15/12

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Wave Life Sciences Ltd.

Acciones

WVE

SG9999014716

Otros idiomas

Filtros